

Article

Bioassay-Guided Isolation and Identification of Cytotoxic Compounds from *Gymnosperma glutinosum* Leaves

Ramiro Quintanilla-Licea ^{1,*}, Rolando Morado-Castillo ¹, Ricardo Gomez-Flores ², Hartmut Laatsch ³, María Julia Verde-Star ¹, Humberto Hernández-Martínez ², Patricia Tamez-Guerra ², Reyes Tamez-Guerra ² and Cristina Rodríguez-Padilla ²

¹ Departamento de Química, Facultad de Ciencias Biológicas, Universidad Autónoma de Nuevo León, Av. Universidad S/N, Cd. Universitaria, San Nicolás de los Garza 66451, Nuevo León, Mexico

² Departamento de Microbiología e Inmunología, Facultad de Ciencias Biológicas, Universidad Autónoma de Nuevo León, Av. Universidad S/N, Cd. Universitaria, San Nicolás de los Garza 66451, Nuevo León, Mexico

³ Institute of Organic and Biomolecular Chemistry, Georg-August-University of Göttingen, Tammannstrasse 2, Göttingen D-37077, Germany

* Author to whom correspondence should be addressed; E-Mail: Ramiro.quintanillalc@uanl.edu.mx; Tel.: +52-81-8376-3668.

Received: 16 July 2012; in revised form: 7 September 2012 / Accepted: 10 September 2012 /

Published: 20 September 2012

Abstract: Bioassay-guided fractionation of hexane extracts of *Gymnosperma glutinosum* (Asteraceae) leaves, collected in North Mexico, afforded the known compounds hentriacontane (**1**) and (+)-13*S*,14*R*,15-trihydroxy-*ent*-labd-7-ene (**2**), as well as the new *ent*-labdane diterpene (–)-13*S*,14*R*,15-trihydroxy-7-oxo-*ent*-labd-8(9)-ene (**3**). In addition, D-glycero-D-galactoheptitol (**4**) was isolated from the methanolic extract of this plant. Their structures were established on the basis of high-field 1D- and 2D NMR methods supported by HR-MS data. The cytotoxic activity was determined by using the *in vitro* L5178Y-R lymphoma murine model. Hentriacontane (**1**) and the new *ent*-labdane **3** showed weak cytotoxicity, whereas the *ent*-labdane **2** showed significant ($p < 0.05$) and concentration dependent cytotoxicity (up to 78%) against L5178Y-R cells at concentrations ranging from 7.8 to 250 µg/mL.

Keywords: *Gymnosperma glutinosum*; asteraceae; Mexican medicinal plant; lymphoma cells; cancer; *ent*-Labdane diterpenes


1. Introduction

Cancer is still the second leading cause of death in industrialized countries [1]. The fate of many cancer patients, for whom cure of their disease is not a reality, is becoming ever more an issue. As repeatedly shown by the National Cancer Institute (USA), more than two thirds of the anticancer drugs approved between the 1940s and 2006 are either natural products or were developed based on the knowledge gained from natural products [2–5].

Phytotherapy represents the oldest form of therapy worldwide; more than 21,000 plant species are used in herbal medicines, according to the World Health Organization [1]. In particular, phytotherapy is practiced by a large part of the Mexican population for the treatment of many diseases. To promote the proper use of herbal medicines and to determine their potential use as source for new drugs, it is essential to study medicinal plants and scientifically validate their use [6–9]. This is the case for *Gymnosperma glutinosum* (Spreng.) Less, (Asteraceae) variously known in Mexico as *Tatalencho*, *Jarilla*, *Mota*, *Hierba Pegajosa*, *Escobilla* and *Pegajosa* [10], which is traditionally used to treat diarrhea, ulcers and rheumatism [11]. This shrubby, monotypic plant is distributed from Guatemala throughout Mexico to the southwestern region of the United States [12,13]. It is closely related to the *Gutierrezia* genus, small shrubby plants with slender stems that are herbaceous above and woody near the base, covered from summer through fall with masses of tiny yellow flowers borne in terminal clusters. The stems, leaves and flowering heads are covered with a glutinous or sticky substance.

It has been reported that *Gymnosperma glutinosum* contains essential oils [14], flavonoids [15–19] and diterpenes [20–24], and recent studies have validated the ethnobotanical use of this plant in Mexico [24–26]. Gomez-Flores *et al.* showed anti-tumor activity of the hexane extract of *G. glutinosum* leaves against L5178Y-R lymphoma cells [27]; we have expanded our investigation on this plant by elucidating the chemical structure of the putative bioactive compounds present in *G. glutinosum*. We describe now the bioassay-guided isolation of hentriacontane (**1**), (+)-13*S*,14*R*,15-trihydroxy-*ent*-labd-7-ene (**2**) and (–)-13*S*,14*R*,15-trihydroxy-7-oxo-*ent*-labd-8(9)-ene (**3**), a new *ent*-labdane diterpene, as well as D-glycero-D-galactoheptitol (**4**). The structure of these compounds (Figure 1) was elucidated by analysis of the spectroscopic data and their cytotoxic activity was determined by using the *in vitro* L5178Y-R lymphoma murine model [27].

Figure 1. Structures of compounds 1–4.



2. Results and Discussion

2.1. Structure Elucidation

The structures of the known compounds **1**, **2** and **4** were established by comparison of their spectroscopic data with literature values. Hentriacontane (**1**), a solid long-chain alkane (C₃₁H₆₄), is found in a variety of plants [28,29], but it has not yet been isolated from *G. glutinosum*. The occurrence of the *ent*-labdane diterpene **2** (C₂₀H₃₆O₃) in *G. glutinosum* has been reported in the literature [22], but no biological activity was described so far.

Compound **3** was isolated as a colorless oil with $[\alpha]_D^{20} = -16.5$ (c 2.0, CHCl₃). (+)-ESI MS exhibited an ion peak [M+Na]⁺ at $m/z = 361$ (C₂₀H₃₄O₄Na) and HR-ESI-MS showed an [M+H]⁺ ion at $m/z = 339.25300$, confirming a molecular formula of C₂₀H₃₄O₄. The ¹H-NMR spectrum (Table 1) showed five methyl singlets at $\delta_H = 0.85, 0.87, 1.05, 1.22$ and 1.72 , characteristic signals of a labdane diterpene skeleton [30–32]. The ¹³C-NMR spectrum of **3** (Table 1), in agreement with the molecular formula, revealed signals corresponding to 20 carbon atoms. Analysis of the ¹³C-NMR and DEPT 135 spectral data with the aid of the HSQC spectra, led to the deduction of the multiplicities of the carbon atoms and established the presence of five methyl signals (11.3, 18.1, 21.3, 22.7, 32.5), two tetrasubstituted olefinic carbons (130.1, 168.6), seven aliphatic methylenes (18.6, 23.1, 35.1, 35.9, 36.4, 41.2, 63.2), two methines (50.2, 70.2), one oxygenated quaternary carbon (74.4), one carbonyl group (200.5), and two quaternary carbons (33.1, 41.1). The above signals and an ABX system in the ¹H-NMR spectrum of **3** for protons geminal to hydroxyl functions (one methylene ($\delta_H = 3.69$, m, 2H; $\delta_C = 63.2$) and one methine ($\delta_H = 3.49$, m, 1H; $\delta_C = 77.2$) corresponding to a primary and secondary alcohol) indicated a diterpene with *ent*-labdane skeleton whose structure is similar to the (+)-13*S*,14*R*,15-trihydroxy-*ent*-labd-7-ene (**2**) previously isolated by Maldonado from *Gymnosperma glutinosum* [22].

Table 1. ¹H (400 MHz) and ¹³C-NMR (100 MHz) data of compound **3** (CDCl₃).


Position	¹³ C		¹ H
	δ	(DEPT)	δ , mult, (<i>J</i> in Hz)
1	35.9	CH ₂	1.27 m, 1.85 m
2	18.6	CH ₂	1.45 m, 1.54 m
3	41.2	CH ₂	1.16 m, 1.40 m
4	33.1	C _q	-
5	50.2	CH	1.67 m
6	35.1	CH ₂	2.31 m, 2.41 m
7	200.5	C=O	-
8	130.1	C _q	-
9	168.6	C _q	-
10	41.1	C _q	-
11	23.1	CH ₂	2.22 m, 2.36 m
12	36.4	CH ₂	1.43 m, 1.64 m
13	74.4	C _q	-
14	77.2	CH	3.49 m
15	63.2	CH ₂	3.69 m

Table 1. Cont.

Position	¹³ C		¹ H
	δ	(DEPT)	δ, mult, (J in Hz)
16	22.7	CH ₃	1.22 s
17	11.3	CH ₃	1.72 s
18	32.5	CH ₃	0.85 s
19	21.3	CH ₃	0.87 s
20	18.1	CH ₃	1.05 s
OH			3.60 br s

Furthermore, comparison of the ¹H- and ¹³C-NMR spectral data of **3** with **2** allowed the assignment of **3** as (–)-13*S*,14*R*,15-trihydroxy-7-oxo-*ent*-labd-8(9)-ene, as compound **3** did not show any olefinic proton signal in the ¹H-NMR spectrum ($\delta_{\text{H}} = 5.37$ in **2**), and in the ¹³C-NMR spectrum only two signals for methine carbons (three methine signals in **2**) were present, but additionally a ketocarbonyl signal ($\delta_{\text{C}} = 200.5$) was found. An ABX signal at $\delta_{\text{H}} 2.31/2.41$, not present in the spectrum of **2**, showed an HMBC coupling with the carbonyl group ($\delta_{\text{C}} = 200.5$) and a COSY correlation with H-5 ($\delta_{\text{H}} = 1.67$). It corresponds therefore to CH₂-6, indicating a change of the double bond in **2** from position Δ^7 to position Δ^8 in **3** as well as the presence of a carbonyl function at carbon 7 in **3**. This was confirmed by the HMBC correlation of Me-17 with CO-7 (and C-8, 9) and by the coupling of Me-20 with the β -olefinic carbon C-9. Further HMBC couplings are summarized in Figure 2.

Figure 2. Selected H,H COSY (\leftrightarrow) and HMBC (\rightarrow) correlations of diterpene **3** in CDCl₃.



3

The IR spectrum of **3** displayed accordingly absorption bands at 1640, 1690 and 3370 cm⁻¹, corresponding to a double bond, an α,β -unsaturated keto group and hydroxyl functions. We assume in **3** the same configuration as in **2** for the respective chiral carbons (5, 10, 13 and 14), as **3** is probably formed by oxidation of **2** in the plant cells.

A labdane keto-triol **6** quite similar to **3** was obtained [33] after a microbiological transformation of 13*R*,14*R*,15-trihydroxylabd-7-ene **5** (Figure 3), a diterpene commonly found in *Madia* species [34,35], as well as in *Blepharizona plumosa* [36]; **5** is a diastereomer of the *ent*-labdan **2** isolated from *G. glutinosum*. As expected, the NMR values of the pseudoenantiomeric labdane keto-triol **6** [33] are very similar to those of **3**. The main difference between both compounds is the chemical shift of C-14 ($\delta_{\text{C}} = 77.2$ in **3**, $\delta_{\text{C}} = 74.9$ in the reported diastereomeric labdane **6**). This seems to be due to a change in the chirality of C-13, which in **2** and **3** is (*S*) but (*R*) in the labdane diterpene from *Madia* species. The configurations on the carbons 13 (*R*) and 14 (*R*) in labdane **6** (Figure 4) would allow hydrogen bonding between the hydroxyl groups that probably diminishes the electronegative effect of the

involved oxygen atoms and might result in increased shielding on these carbons and consequently leads to the high field chemical shift of C-14 ($\delta_C = 74.9$). In *ent*-labdane **3** hydrogen bonding (like in labdane **6**) should be expected preferentially between 13-OH and 15-OH which thus leads to the low field chemical shift of C-14 ($\delta_C = 77.2$). This assumption is nicely confirmed by DFT calculations [37] with predicted shifts close to the experimental values (Figure 4).

Figure 3. Microbiological transformation of labdane **5** into **6** [33].





Figure 4. Conformations and hydrogen bridges of labdane **6** (left partial structure) and *ent*-labdane **3** (right fragment) according to DFT calculations with SPARTAN[®]. The carbon shifts were calculated for solutions in CH₂Cl₂.




There are some differences in the chemical shifts assignments reported by Haridy *et al.* [33] for the ¹³C-NMR spectrum of labdane **6** for the positions 1–3 ($\delta_C = 18.6$, 41.3 and 35.9) in comparison with the signals of our *ent*-labdane **3** ($\delta_C = 35.9$, 18.6, 41.2). The hydrogen and carbon connectivities in **3** were deduced from the ¹H-¹H COSY, HSQC and HMBC spectra (Figure 2). The attachment of methyl groups 18 and 19 at C-4 was clearly illustrated by the cross-peak of methyl signals in the HMBC spectrum at $\delta_C = 32.5$ and 21.3 with H-5 represented by a multiplet centered at $\delta_H = 1.67$ and with CH₂-3 represented by two multiplets at $\delta_H = 1.16$ and 1.40 (HSQC confirms $\delta_C = 41.2$ for C-3). Likewise, the attachment of methyl 20 at C-10 was determined by the cross-peak of the signal at $\delta_C = 18.1$ with H-5 and with CH₂-1 represented by two multiplets at $\delta_H = 1.27$ and 1.85 ($\delta_C = 35.9$ by HSQC for C-1). Our assignments for the chemical shifts of the methylene groups in the positions 1–3 of compound **3** are in agreement with other literature values reported for the labdane skeleton [24,31,32] and are also reproduced by prediction programs like the ACD/CNMR Predictor 89 [38].

Finally, from the methanol extract of *G. glutinosum*, D-perseitol (**4**), a known naturally occurring heptitol [39,40], was isolated for the first time from this plant. The physical and optical properties of the isolated perseitol are sufficiently different from the diastomeric heptitols D-volemitol and D- β -sedoheptitol, isolated from other plants [41,42].

2.2. Cytotoxicity Activity


The cytotoxic activity of the extracts of *G. glutinosum* and compounds 1–4 was determined by using the *in vitro* L5178Y-R lymphoma murine model [27]. Viability of L5178Y-R tumor cells was significantly ($p < 0.05$) reduced by *G. glutinosum* extracts (Figure 5); hexane and methanol extracts caused significant cytotoxicity of 24% and 23%, respectively, at the lowest concentration tested (7.8 $\mu\text{g/mL}$). In addition, fractions SC1 and SC4 obtained from the hexane extract after column chromatography over silica gel, showed the highest cytotoxicity of 45% and 27%, respectively, at 31.2 $\mu\text{g/mL}$ (Figure 5).

Figure 5. Cytotoxicity of extracts and fractions SC1 to SC4 from hexane extract of *Gymnosperma glutinosum* against L5178Y-R cells *in vitro*, as compared with untreated control (culture medium). Data represent means \pm SD of triplicate determinations from 3 independent experiments. Optical density at 540 nm for untreated cells was 0.53 ± 0.06 .



The bioassay guided purification of fractions SC1 and SC4 from the hexane extract resulted in the isolation and identification of three compounds that were tested for cytotoxic activity against L5178Y-R cells, from which only compound 2 was observed to be cytotoxic. Hentriacontane (1) and the new *ent*-labdane 3 showed not significant cytotoxicity (up to 33% cytotoxicity; data not shown), whereas the *ent*-labdane 2 showed significant ($p < 0.05$) and concentration-dependent cytotoxicity (up to 78%) against L5178Y-R cells at concentrations ranging from 7.8 to 250 $\mu\text{g/mL}$ (Figure 6). The heptitol 4 isolated from the methanolic extract did not show cytotoxicity at any concentration tested.

Figure 6. Cytotoxicity of pure compound 2 from *Gymnosperma glutinosum* against L5178Y-R cells *in vitro*, as compared with untreated control (culture medium). Data represent means \pm SD of triplicate determinations from three independent experiments. Optical density at 540 nm for untreated cells was 0.53 ± 0.06 .



3. Experimental

3.1. General

Melting points were determined on an Electrothermal 9100 apparatus (Electrothermal Engineering Ltd., Southend on Sea, Essex, UK). Optical rotations were recorded on a PolyScience Polarimeter Model SR-6 and on a Perkin Elmer Polarimeter Model 241. IR spectra were recorded on a Varian 1000 FT-IR spectrometer using an ATR accessory. NMR spectra were measured on a Bruker DPX Spectrometer (^1H , 400 MHz; ^{13}C , 100 MHz). ESI HR mass spectra were measured on a Bruker FTICR 4.7 T Mass spectrometer. EI MS was recorded on a Finnigan MAT 95 spectrometer (70 eV). TLC was carried out on pre-coated silica gel glass plates 5×10 cm (Merck silica gel 60 F₂₅₄, Darmstadt, Germany). Normal phase column chromatography was performed on silica gel (60–200 mesh) purchased from J. T. Baker (Phillipsburg, NJ, USA). Size-exclusion chromatography was performed on Sephadex LH-20 (Lipophilic Sephadex, Amersham Biosciences Ltd; purchased from Sigma-Aldrich Chemie, Steinheim, Germany).

3.2. Plant Material

Aerial parts of *G. glutinosum* were collected in Escobedo, Nuevo León, México, in July 2003 and identified by Maria del Consuelo González. A voucher specimen (No. 024247) was deposited at the Herbario de la Facultad de Ciencias Biológicas (UANL), Nuevo León, México.

3.3. Extraction and Isolation

Ground and dried leaves of *Gymnosperma glutinosum* (200 g) were sequentially extracted by maceration with 1 L *n*-hexane, chloroform and methanol. After filtration, the solvent was removed under reduced pressure to yield 20.5, 39.9 and 39.4 g of extract, respectively. Each extract was analyzed for cytotoxic activity (Figure 5). The hexane extract, which was more active than the others at low concentrations, was divided into two portions of ca. 10 g and each of them chromatographed on a silica gel (190 g) column (160 \times 3 cm) and eluted with stepwise gradients of *n*-hexane-chloroform (100:0, 90:10, 80:20, 70:30, 60:40, 50:50, 40:60, 30:70, 20:80, 10:90, 0:100 v/v, each 400 mL), chloroform-ethyl acetate (90:10, 80:20, 70:30, 60:40, 50:50, 40:60, 30:70, 20:80, 10:90, 0:100 v/v, each 400 mL), and finally with 800 mL methanol. A total of 184 subfractions (50 mL) were collected for each column and combined on the basis of their TLC (*n*-hexane-CHCl₃ 1:1) profiles into four main fractions as follows: subfractions 1–43 SC1 (1.6 g), subfractions 44–78 SC2 (2.6 g), subfractions 79–104 SC3 (2.4 g) and subfractions 105–184 SC4 (5.9 g). These main fractions, containing the non-polar to the more polar compounds, were used for cytotoxicity assays (Figure 5). Fractions SC1 and SC4 showed the best activity against L5178Y–R and were submitted to additional fractionation. Fraction SC1 was chromatographed again on a silica gel (20 g) column (36 \times 2 cm) using a stepwise gradient solvent system consisting of *n*-hexane-chloroform (100:0, 90:10, 80:20, 70:30, 60:40, 50:50, 40:60, 30:70, 20:80, 10:90, 0:100 v/v, each 50 mL), chloroform-ethyl acetate (90:10, 80:20, 70:30, 60:40, 50:50, 40:60, 30:70, 20:80, 10:90, 0:100 v/v, each 50 mL), and finally with 100 mL methanol. A total of 115 subfractions (10 mL) were collected, combined on the basis of their TLC (*n*-hexane-CHCl₃

1:1) profiles into eight main fractions as follows: A (subfractions 1–6), B (subfractions 7–21), C (subfractions 22–34), D (subfractions 35–40), E (subfractions 41–49), F (subfractions 50–61), G (subfractions 62–70) and H (subfractions 71–115). Fraction A yielded 200 mg hentriacontane (**1**) whereas fractions B to H were still complex mixtures (NMR) of *n*-alkanes and probably diterpenes. Fraction SC4 was also chromatographed on a silica gel (190 g) column (160 × 3 cm) using a stepwise gradient solvent system consisting of chloroform-ethyl acetate (100:0, 90:10, 80:20, 70:30, 60:40, 50:50, 40:60, 30:70, 20:80, 10:90, 0:100 v/v, each 400 mL), and finally with 800 mL methanol. A total of 260 subfractions (20 mL) were collected, combined on the basis of their TLC (CHCl₃–EtOAc, 1:1) profiles into six main fractions as follows: I (subfractions 1–36), J (subfractions 37–60), K (subfractions 61–92), L (subfractions 93–143), M (subfractions 143–182) and N (subfractions 183–260). Fraction L produced almost pure (+)-13*S*,14*R*,15-trihydroxy-*ent*-labd-7-ene (**2**) whereas fraction M rendered (–)-13*S*,14*R*,15-trihydroxy-7-oxo-*ent*-labd-8(9)-ene (**3**). Both diterpenes were subjected to additional purification on a Sephadex LH-20 (50 g) column (160 × 1.5 cm), using MeOH as eluent. For diterpene **2** a total of 240 subfractions (10 mL) were collected and after combining subfractions 17–20, previously purity judged from TLC (CHCl₃–EtOAc, 1:1), 2.5 g of (+)-13*S*,14*R*,15-trihydroxy-*ent*-labd-7-ene (**2**) were obtained. For diterpene **3** only 190 subfractions (10 mL) were collected. From subfractions 14–18, combined on the basis of their TLC (CHCl₃–EtOAc, 1:1) profiles, 600 mg of (–)-13*S*,14*R*,15-trihydroxy-7-oxo-*ent*-labd-8(9)-ene (**3**) were obtained.

After cooling, an amorphous precipitate was formed from the methanol extract, which was collected and stirred in 30 mL cold methanol for 24 h. After filtration, 250 mg of D-glycero-D-galactoheptitol (**4**) were recovered as a white powder.

(–)-13*S*,14*R*,15-Trihydroxy-7-oxo-*ent*-labd-8(9)-ene (**3**). Colorless oil; $R_f = 0.18$ (CHCl₃–EtOAc, 1:1); $[\alpha]_D^{20}$: –16.5 (c 2.0, CHCl₃); IR (ATR): $\nu_{\max} = 3370, 2915, 1710, 1690, 1640, 1462, 1372, 1018, 720 \text{ cm}^{-1}$; ¹H- and ¹³C-NMR data in CDCl₃, see Table 1; ESI-MS (+)-mode: $m/z = 361$ [M+Na]⁺, (–)-mode: $m/z = 337$ [M–H][–]; (+)-ESI HR MS: $m/z = 339.25300$ [M+H]⁺ (calcd. for C₂₀H₃₅O₄: 339.25298).

3.4. Cytotoxicity Assay

3.4.1. Reagents and Culture Medium

Penicillin-streptomycin solution, L-glutamine, and RPMI 1640 medium were obtained from Life Technologies (Grand Island, NY, USA). Fetal bovine serum (FBS), sodium dodecyl sulfate (SDS), N,N-dimethylformamide (DMF) and 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) were purchased from Sigma-Aldrich Co. (St. Louis, MO, USA). Vincristine sulfate salt (97.5%) was obtained from Vintec (Columbia S. A. de C. V., México). Extraction buffer was prepared by dissolving 20% (wt/vol) SDS at 37 °C in a solution of 50% each DMF and demineralized water, and the pH was adjusted to 4.7.

3.4.2. Tumor Cell Line

The tumor cell line L5178Y-R (mouse DBA/2 lymphoma) was purchased from The American Type Culture Collection (Rockville, MD, USA) and was maintained in culture flasks with RPMI 1640

medium supplemented with 10% FBS, 1% L-glutamine, and 0.5% penicillin-streptomycin solution (referred as complete RPMI medium) at 37 °C, in a humidified atmosphere of 5% CO₂ in air. Cellular density was kept between 10⁵ and 10⁶ cells/mL.

3.4.3. Cell Preparation and Culture

The direct *in vitro* activity of extracts, active fractions and pure compounds of *Gymnosperma glutinosum* was carried out by the tetrazolium bromide (MTT) colorimetric technique [27]. Cell cultures were collected, washed three times in RPMI 1640 and adjusted to 5 × 10⁴ cells/mL with RPMI complete medium. One hundred microliters of the cell suspension were then added to flat-bottomed 96-well plates (Becton Dickinson, Cockeysville, MD, USA), containing triplicate cultures (100 µL) of *G. glutinosum* extracts, active fractions or pure compounds at various concentrations as well as positive (vincristine) and negative (culture medium) controls. The plates were then incubated for 44 h at 37 °C in 5% CO₂ atmosphere. Next, 0.5 mg/mL of MTT were added, and the cultures were additionally incubated for 4 h. After this, 100 µL extraction buffer were added to all wells and plates were incubated for 16 h and optical densities, resulting from dissolved formazan crystals, were then read in a microplate reader (Bio-Tek Instruments, Inc., Winooski, VT, USA) at 540 nm. The results were expressed as mean ± SD of triplicate determinations from a representative experiment. All experiments were repeated at least three times with similar results. Statistical significance was assessed by one-way analysis of variance. Cytotoxicity percentage was determined as follows:

$$\% \text{ Cytotoxicity} = 100 - \frac{A_{540} \text{ in } G. \text{ glutinosum} - \text{ treated cells}}{A_{540} \text{ in untreated cells}} \times 100$$

4. Conclusions

Hentriacontane (**1**) has already been suggested as a possible antitumor agent [43,44], however, in our case, it showed non-significant 12% cytotoxicity at 250 µg/mL (data not shown). The heptitol **4** did not show cytotoxicity at any concentration tested, although a complex with K⁺ ions has been shown to exhibit a potent inhibitory effect on [³H]-leucine incorporation for protein synthesis on Ehrlich ascites tumor cells in mice [40,45]. Our results showed significant tumor cell toxicity of the apolar *ent*-labdane **2** of up to 78% (250 µg/mL) in a concentration-dependent fashion, from concentrations as low as 7.8 µg/mL, as compared with untreated control, which may be an indication of an important antitumor activity (Figure 6), whereas *ent*-labdane **3** (polar) only caused low but significant (*p* = 0.05) 32% cytotoxicity at 250 µg/mL (data not shown). Vincristine control caused 68% to 81% cytotoxicity at concentrations ranging from 0.49 to 31.25 µg/mL respectively (data not shown). Cytotoxicity observed by the hexane extract (Figure 5) may be the result of the additive effect of all labdane-diterpenes in the extract. Separation of the polar and apolar diterpenes **3** and **2** shows that these compounds probably have to cross a lipophilic barrier in the lymphoma cell in order to induce cytotoxicity. The polar diterpene **3** is clearly significantly less effective to cross this barrier and therefore did not show significant cytotoxicity as pure compound. In our study, we decided to fractionate only the hexane extract, which was more active than the others at low concentrations (7.8 µg/mL). The chloroform extract was not successfully fractionated, however, our preliminary

findings showed that this extract is a complex mixture of labdane diterpenes (5 singlets between δ 1.7 and 0.7 in the $^1\text{H-NMR}$ spectrum; [24,31,32]) and highly oxygenated flavonoids (signals for aromatic protons and methoxy groups between δ 3.5 and 4.5 in the $^1\text{H-NMR}$ spectrum [18,19]; data not shown). Diterpenes of the labdane type have been reported to have a broad spectrum of biological activities [46]. Many studies have shown that labdane diterpenes exhibit significant cytotoxic and cytostatic effects against leukemic cell lines of human origin and interfere with the biochemical pathways of apoptosis and the cell cycle phases, as well as with the expression of several protooncogenes such as *c-myc* and *bcl-2* [47]. The cytotoxic activity of the *ent*-labdane diterpenes from *G. glutinosum* indicated that natural products from plants might contribute to the pool of novel anticancer drugs for which tumor resistance may not have been developed [48].

Acknowledgements

The authors would like to thank the DAAD (Germany), who financed a stay of R.Q.L. at the University of Göttingen. We also thank the Universidad Autónoma de Nuevo León (Mexico) for PAICYT grants CN892-04, CN1097-05 and CN-1570-07, as well as the CONACYT (Mexico) for grant 52318 to RQL. For the spectroscopic measurements, we thank H. Frauendorf and R. Machinek of the University of Göttingen (Germany) and Prof. Noemi Waksman of the College of Medicine from Universidad Autónoma de Nuevo León.

Supplementary Materials

Supplementary materials can be accessed at: <http://www.mdpi.com/1420-3049/17/9/11229/s1>.

References

1. Efferth, T. Cancer therapy with natural products and medicinal plants. *Planta Med.* **2010**, *76*, 1035–1036.
2. Newman, D.J.; Cragg, G.M. Natural products as sources of new drugs over the last 25 years. *J. Nat. Prod.* **2007**, *70*, 461–477.
3. Newman, D.J. Natural products as leads to potential drugs: An old process or the new hope for drug discovery? *J. Med. Chem.* **2008**, *51*, 2589–2599.
4. Harvey, A.L. Natural products in drug discovery. *Drug Discov. Today* **2008**, *13*, 894–901.
5. Jesse, W.H.L.; Vederas, J.C. Drug discovery and natural products: end of an era or an endless frontier? *Science* **2009**, *325*, 161–165.
6. Alonso-Castro, A.J.; Villarreal, M.L.; Salazar-Olivo, L.A.; Gomez-Sanchez, M.; Dominguez, F.; Garcia-Carranca, A. Mexican medicinal plants used for cancer treatment: Pharmacological, phytochemical and ethnobotanical studies. *J. Ethnopharmacol.* **2011**, *133*, 945–972.
7. Jiménez-Arellanes, M.A.; Cornejo-Garrido, J.; León-Díaz, R. Mexican medicinal plants as a source of antimycobacterial compounds. *Rev. Mex. C. Farm.* **2010**, *41*, 22–29.
8. Navarro-García, V.M.; Gonzalez, A.; Fuentes, M.; Aviles, M.; Rios, M.Y.; Zepeda, G.; Rojas, M.G. Antifungal activities of nine traditional Mexican medicinal plants. *J. Ethnopharmacol.* **2003**, *87*, 85–88.

9. Heinrich, M. Arzneipflanzen Mexikos. *Deutsche Apotheker Zeitung* **1996**, *136*, 1739–1752.
10. González-Elizondo, M.; López-Enrique, I.L.; González-Elizondo, M.S.; Tena-Flores, J.A. *Plantas Medicinales Del Estado de Durango y Zonas Aledañas*; Instituto Politécnico Nacional: México, D.F., Mexico, 2004; p. 134.
11. Casas, A.; Valiente-Banuet, A.; Viveros, J.L.; Caballero, J.; Cortés, L.; Dávila, P.; Lira, R.; Rodríguez, I. Plant resources of the Tehuacán-Cuicatlán Valley, Mexico. *Econ. Bot.* **2001**, *55*, 129–166.
12. Valiente-Banuet, A.; Flores-Hernández, N.; Verdú, M.; Dávila, P. The chaparral vegetation in Mexico under non-mediterranean climate: the convergence and Madrean-Tethyan hypotheses reconsidered. *Am. J. Bot.* **1998**, *85*, 1398–1408.
13. Lane, M.A. Systematics of *Amphiachyris*, *Greenella*, *Gutierrezia*, *Gymnosperma*, *Thurovia* and *Xanthocephalum* (Compositae:Astereae). Ph.D. Thesis, University of Texas, Austin, TX, USA, 1980.
14. Domínguez, X.A.; Torre, B. Two pentamethoxylated flavonoids from *Gymnosperma glutinosum*. *Phytochemistry* **1974**, *13*, 1624–1625.
15. Wollenweber, E.; Dietz, V.H. Occurrence and distribution of free flavonoid aglycones in plants. *Phytochemistry* **1981**, *20*, 869–932.
16. Yu, S.; Fang, N.; Mabry, T.J. Flavonoids from *Gymnosperma glutinosum*. *Phytochemistry* **1988**, *27*, 171–177.
17. Iinuma, M.; Mitzuno, M. Natural occurrence and synthesis of 2'-oxygenated flavones, flavonols, flavonones and chalcones. *Phytochemistry* **1989**, *28*, 681–694.
18. Wollenweber, E.; Dörr, M.; Fritz, H.; Papendieck, S.; Yatskievych, G.; Roitman, J.N. Exudate flavonoids in Asteraceae from Arizona, California and Mexico. *Z. Naturforsch.* **1997**, *52C*, 301–307.
19. Horie, T.; Ohtsuru, Y.; Shibata, K.; Yamashita, K.; Tsukayama, M.; Kawamura, Y. ¹³C-NMR Spectral assignment of the A-ring of polyoxygenated flavones. *Phytochemistry* **1998**, *47*, 865–874.
20. Miyakado, M.; Ohno, N.; Yosioka, H.; Mabry, T.J.; Whiffin, T. Gymnospermin: A new labdan triol from *Gymnosperma glutinosa*. *Phytochemistry* **1974**, *13*, 189–190.
21. Martínez, R.; Calderón, J.S.; Toscano, R.A.; Valle-Aguilera, L.; Mendoza-Candelaria, H.M. Ent-neoclerodane diterpenes from *Gymnosperma glutinosum*. *Phytochemistry* **1994**, *35*, 1505–1507.
22. Maldonado, E.; Segura-Correa, R.; Ortiga, A.; Calderón, J.S.; Fronczek, F.R. Ent-Labdane and neo-Clerodane diterpenes from *Gymnosperma glutinosum*. *Phytochemistry* **1994**, *35*, 721–724.
23. Calderón, J.S.; Segura-Correa, R.; Céspedes, C.L.; Toscano, R.A. Crystal and molecular structure of (–)-17-hydroxy-neo-clerod-3-en-15-oic acid from *Gymnosperma glutinosum*. *Anal. Sci.* **2001**, *17*, 1467–1468.
24. Serrano, R.; Hernández, T.; Canales, M.; García-Bores, A.M.; Romo-De-Vivar, A.; Céspedes, C.L.; Avila, J.G. Ent-labdane type diterpene with antifungal activity from *Gymnosperma glutinosum* (Spreng.) Less. (Asteraceae). *BLACPMA* **2009**, *8*, 412–418.

25. Canales, M.; Hernández, T.; Serrano, R.; Hernández, L.B.; Duran, A.; Ríos, V.; Sigríst, S.; Hernández, H.L.H.; Garcia, A.M.; Angeles-López, O.; *et al.* Antimicrobial and general toxicity activities of *Gymnosperma glutinosum*: A comparative study. *J. Ethnopharmacol.* **2007**, *110*, 343–347.
26. Gomez-Flores, R.; Arzate-Quintana, C.; Quintanilla-Licea, R.; Tamez-Guerra, P.; Tamez-Guerra, R.; Monreal-Cuevas, E.; Rodríguez-Padilla, C. Antimicrobial activity of *Persea americana* Mill (Lauraceae) (Avocado) and *Gymnosperma glutinosum* (Spreng.) Less (Asteraceae) Leaf Extracts and Active fractions against *Mycobacterium tuberculosis*. *Am.-Euras. J. Sci. Res.* **2008**, *3*, 188–192.
27. Gomez-Flores, R.; Verástegui-Rodríguez, L.; Quintanilla-Licea, R.; Tamez-Guerra, P.; Monreal-Cuevas, E.; Tamez-Guerra, R.; Rodríguez-Padilla, C. Antitumor Properties of *Gymnosperma glutinosum* Leaf Extracts. *Cancer. Invest.* **2009**, *27*, 149–152.
28. Dargaeva, T.D.; Brutko, L.I. Hentriacontane from *Scabiosa comosa*. *Chem. Nat. Comp.* **1976**, *12*, 471.
29. Tessmann, D.J.; Dianese, J.C. Hentriacontane: A leaf hydrocarbon from *Syzygium jambos* with stimulatory effects on the germination of uredinospores of *Puccinia psidii*. *Fitopatol. Bras.* **2002**, *27*, 538–542.
30. Vardamides, J.C.; Sielinou, V.T.; Ndemangou, B.; Nkengfack, A.E.; Formum, Z.T.; Poumale, H.M.P.; Laatsch, H. Diterpenoids from *Turraeanthus mannii*. *Planta Med.* **2007**, *73*, 491–495.
31. Pérez-Castorena, A.L.; Oropeza, R.F.; Vázquez, A.R.; Martínez, M.; Maldonado, E. Labdanes and Withanolides from *Physalis coztomatl*. *J. Nat. Prod.* **2006**, *69*, 1029–1033.
32. Lee, S.O.; Choi, S.Z.; Choi, S.U.; Lee, K.C.; Chin, Y.W.; Kim, J.; Kim, Y.C.; Lee, K.R. Labdane diterpenes from *Aster spathulifolius* and their cytotoxic effects on human cancer cell lines. *J. Nat. Prod.* **2005**, *68*, 1471–1474.
33. Haridy, M.S.A.; Ahmed, A.A.; Doe, M. Microbiological transformation of two labdane diterpenes, the main constituents of *Madia* species, by two fungi. *Phytochemistry* **2006**, *67*, 1455–1459.
34. Bohlmann, F.; Jakupovic, J.; King, R.M.; Robinson, H. New labdane derivatives from *Madia sativa*. *Phytochemistry* **1982**, *21*, 1103–1107.
35. Wollenweber, E.; Dörr, M.; Dörsam, M. Flavonoids and terpenoids from the resinous exudates of *Madia* species (Asteraceae, Helenieae). *Z. Naturforsch.* **2003**, *58C*, 153–160.
36. Jolad, S.D.J.; Hoffmann, J.J.; Timmermann, B.N.; Bates, R.B.; Camou, F.A.; McLaughlin, S.P. Diterpenoids and acetogenins of *Blepharizonia plumose*. *Phytochemistry* **1990**, *29*, 905–910.
37. Wavefunction Inc. Calculated with DFT B3LYP 6–31G* using SPARTAN'08. Wavefunction Inc.: Irvine, CA, USA, 2008.
38. Advanced Chemistry Development Inc. ACD/C+H-NMR Predictors, Release 12.00. Advanced Chemistry Development Inc.: Toronto, ON, Canada, 2008.
39. Jones, J.K.N.; Wall, R.A. Isolation of D-Glycero-D-galacto-heptitol from the Wound Exudate of Avocado Trees. *Nature* **1961**, *189*, 746.
40. Ishizu, T.; Winarno, H.; Tsujino, E.; Morita, T.; Shibuya, H. Indonesian Medicinal plants. XXIV. Stereochemical structure of perseitol K⁺ complex isolated from the leaves of *Scurrula fusca* (Loranthaceae). *Chem. Pharm. Bull.* **2002**, *50*, 489–492.

41. Richtmeyer, N.K.; Hudson, C.S. The rotation of polyols in ammonium molybdate solutions. *J. Am. Chem. Soc.* **1951**, *73*, 2249–2250.
42. Kanters, J.A.; Schouten, A.; van der Louis, S.; Duisenberg, A.J.M. Structure of D-perseitol (D-glycero-D-galacto-heptitol). *Acta Cryst.* **1990**, *C46*, 71–74.
43. Takahashi, C.; Kikuchi, N.; Katou, N.; Miki, T.; Yanagida, F.; Umeda, M. Possible anti-tumor-promoting activity of components in Japanese soybean fermented food, Natto: Effect of gap junctional intercellular communication. *Carcinogenesis* **1995**, *16*, 471–476.
44. Dias, J.M.M.; Chavez, C.P. Combination of active fractions from the plants *Euphorbia tirucalli* L. and *Ficos carica* L. and methods of treating cancer and aids. PCT Int. Appl. 2006007676, 2006.
45. Kadota, K.; Ogasawara, K.; Iwabuchi, Y. A diastereocontrolled synthesis of perseitol using a dioxabicyclo[3.2.1]octane chiral building block. *ARKIVOC* **2003**, *viii*, 163–170.
46. Chinou, I. Labdanes of natural origin—Biological activities (1981–2004). *Curr. Med. Chem.* **2005**, *12*, 1295–1317.
47. Demetzos, C.; Dimas, K.Z. Labdane-type diterpenes: Chemistry and biological activity. In *Studies in Natural Product Chemistry*; Atta-ur-Rahman, Ed.; Elsevier Science B.V: Amsterdam, The Netherlands, 2001; Volume 25, pp. 235–292.
48. Singh, M.; Pal, M.; Sharma, R.P. Biological activity of the labdane diterpenes. *Planta Med.* **1999**, *65*, 2–8.

Sample Availability: Samples of the compounds **1–4** are available from the authors.

© 2012 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (<http://creativecommons.org/licenses/by/3.0/>).